제넥신

095700KOSDAQ

63.8 / 100

Reference Date: 2026-09-08

Financial Score23.5 / 40

News Sentiment21.3 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 15.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genexine focuses on developing innovative therapies for cancer and immune-related diseases using its proprietary bioPROTAC technology, which leverages biologics like nanobodies to overcome limitations of traditional small-molecule-based PROTAC approaches. The company aims to effectively degrade target proteins by utilizing advanced targeted protein degradation techniques, enabling precise and efficient disease treatment.

Number of Employees

68people

Average Salary

82.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.56Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-10.71Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

3.10Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.9% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
모더나 암백신 3상 성공에…삼양바이오팜 상한가
제넥신의 주가가 모더나와 공동 개발한 mRNA 암 백신의 임상 성공 소식에 힘입어 상한가를 기록했다.
Positive
[대학·기업 손잡고 국가 혁신, OIRC]〈4〉가톨릭대 OIRC, 막강...
제넥신과 관련된 혁신적인 산학 협력이 국가적 차원에서 진행되어 바이오 및 의생명공학 분야의 고부가가치 창출과 국민 건강 개선에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 3,055Won52-week high 7,10052-week low 2,195

1-month return6.0Point

1m +15.72% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식매수선택권부여에관한신고2026-08-24
Neutral투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)2026-08-21
Neutral반기보고서 (2026.06)2026-08-13